Search

Background: Telepathology practice across international borders has become increasingly popular. Our telepathology consultation service with a laboratory in China was hampered by latency issues when viewing whole slide images. Objective: The aim was to explore data transfer solutions to improve the viewing experience of digital consult cases. Methods: Whole slide image files residing on a server in China were transferred to our data center in the USA using an open source product (Fast Data Transfer). A faster more automated commercial high speed file transfer software solution (Aspera) was also tested. Results: Transferring files with the open source product provided transfer speeds of 2-3 Mbps, but suffered from intermittent dropped connections. Employing commercial software permitted more reliable transmission of digital files with 75-100 Mbps transfer speeds. Conclusions: Successful global telepathology requires dedicated image management. Transfer of files to local servers by employing high speed data transfer tools helped overcome network latency issues, improved the overall turn-around time of digital consultations, and enhanced the viewing experience for end-user digital consultants. [ABSTRACT FROM AUTHOR]

Diabetes mellitus is the global health issue and become an alarming threat in the modern era where human lifestyle gets compromised with modernization. According to the latest statistical report 2020, USA has 9.47% (31 million among 32.72 cr), China has 8.3% (116.4 million among 139.27 cr) and India has 5.6% (77 million among 135.26 cr) of the diabetic people, indicating that diabetes is more prevailing in developed countries as compared to the developing countries. The number of diabetic patients is rising day by day at a tremendous rate and soon it may affect each and every person in a family. So, there is an urgent need to develop novel entities that can meet the scarcity of present antidiabetic agents. In the last few decades, the sodium-glucose co-transporter 2 (SGLT2) has emerged as a prominent target for the treatment of Type 2 diabetes mellitus due to its novel mechanism of action & no involvement in insulin signaling pathway. Most of the inhibitors that target SGLT2 contain three basic moieties: glucose, two benzene rings (one is connected with glucose and the other with methylene), and the methylene bridge which are similar to dapagliflozin. Several SGLT2 inhibitors and their derivatives such as remogliflozin etabonate (phase-II), sotagliflozin (phase-III) and bexagliflozin (phase-III) are under different phases of clinical trial studies and some have been patented. The present review is focused on SGLT2 inhibitors, structure activity relationships (SARs) of dapagliflozin and its several analogues for their binding affinity with SGLT2. We have also presented and summarized the efforts made by various researchers in terms of the synthesis of various dapagliflozin derivatives till date. Image 1 • Global impact in terms of statistical overview regarding type2 diabetes mellitus. • hSGLT2 as potential target for development of novel anti-diabetic agents. • Structural insights of hSGLT2and its inhibitors. • SAR studies to know the effect of different substituents of SGLT2 inhibitors. [ABSTRACT FROM AUTHOR]